cyrilzakka/clinical-trials huggingface dataset:
Validation of the French Adaptation of the MSWDQ-23 Questionnaire

MS is an autoimmune disease of the central nervous system that affects more than 120,000 people in France. The average age of onset of the disease is between 25 and 35 years. Given the wide range of ages of the patients, from 4 to 80 years, the ethical and socio-economic stakes are high in order to maintain their autonomy, sociability, family and intimate life, and their employment in the best possible conditions and for as long as possible.

However, to date, there are no evaluation tools in French that allow us to understand the difficulties at work of MS patients.

The Multiple Sclerosis Work Difficulties Questionnaire (MSWDQ-23) was developed specifically for MS patients and validated in English \[1\]. There is a short version of this questionnaire that facilitates its use in clinical practice \[2\]. It has been translated and validated in Spanish through a multicenter study, and is currently being validated in German, but does not currently exist in French \[3\]. The main objective of the WORKSEP project is to validate the French version of this questionnaire through a multicenter population-based cohort within the framework of the French-speaking Multiple Sclerosis Society (SFSEP). This validation study will involve the inclusion of 206 French-speaking MS patients, regardless of their professional status, all forms of MS combined, from the early stage (Clinically Isolated Syndrome) to the more advanced stages (primary and secondary progressive forms).


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 65 years old.
* Native French speaker.
* A diagnosis of Clinically Isolated Syndrome or MS defined according to the 2017 McDonald criteria.
* Be affiliated with the social security system.
* Agree to participate in the study.

Exclusion Criteria:

Opposition to the use of the data
Daily Magnesium-treatment of Patients With Chronic Obstructive Pulmonary Disease

The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease.

The aim of this part of the project is to study the effect of a daily magnesium supplement for COPD-patients


Eligibility Criteria:
Inclusion Criteria:

* COPD-patients, grade moderate-severe (FEV1 30-80 % of expected. FEV1/FVC \< 0,7).

Exclusion Criteria:

* Se-Mg \> 2,00 mmol/L, smoking cessation less than 1 year prior to study start, submission to hospital within the last two years, submission to hospital with exacerbation during the study period, major changes in eating habits within three months prior to study start and during the study period of approx.one year various conditions (e.g. gastrointestinal disease, kidney disease, pregnancy/lactation) that may affect the study results.
CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide

RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage.

PURPOSE: This clinical trial is looking at the CYP3A5 gene to see if having the gene may be a risk factor for kidney damage in young patients with cancer treated with ifosfamide.

OBJECTIVES:

Primary

* To determine the CYP3A5 genotype in young patients with cancer who have received ifosfamide.
* To document renal function and nephrotoxicity on one occasion between 1 month and 5 years after completion of ifosfamide treatment.
* To determine the relationship between CYP3A5 genotype and ifosfamide nephrotoxicity.

Secondary

* To compare the measured glomerular filtration rate (GFR) (using a radioisotope clearance method) with that calculated using the Cole (weight and creatinine) model.

OUTLINE: This is a multicenter study.

Nephrotoxicity assessment is performed in patients who have not undergone prior assessment\*.

NOTE: \*Nephrotoxicity assessment is performed once between 1 month and 5 years after completion of ifosfamide chemotherapy.

All patients will undergo a single blood sample collection. DNA will be extracted from this sample and genotyped for the known functional polymorphisms in CYP3A5. The technique of restriction fragment length polymorphism (RFLP) will be used to detect any single nucleotide polymorphisms in CYP3A5.

DNA may be obtained from stored tumor samples from patients for whom the results of renal investigations are available, but for whom blood is not available for CYP3A5 genotyping.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Received ifosfamide before the age of 21 as part of treatment for cancer including, but not limited to, any of the following:

  * Ewing sarcoma
  * Rhabdomyosarcoma
  * Non-rhabdomyosarcoma soft tissue sarcoma
* No renal infiltration by tumor at any stage of illness
* May have been treated on one of the following clinical trials:

  * Euro-Ewing-Intergroup-EE99
  * SIOP-MMT-95

    * Patients who received CEV chemotherapy (carboplatin, epirubicin, and vincristine) on strategy 952 or 953 are not eligible
  * CCLG-EPSSG-NRSTS-2005
  * CCLG-EPSSG-RMS-2005

PATIENT CHARACTERISTICS:

* Clinically stable to undergo renal investigations
* No pre-existing renal impairment (glomerular or tubular) prior to treatment with ifosfamide
* No known nephrotoxicity for which nephrotoxic supportive treatment (aminoglycosides, amphotericin, acyclovir, cyclosporine, or tacrolimus) was a major contributory cause of renal damage

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Recovered from the acute non-renal toxicity of the last course of chemotherapy
* No other prior nephrotoxic chemotherapy (e.g., cisplatin, carboplatin, melphalan, or high-dose methotrexate)
* No prior radiotherapy to a field including the kidneys
* No prior removal of renal tissue
* No concurrent ifosfamide
Incidence of Cholelithiasis After Bariatric Surgery in Sohag University Hospital

To study the incidence and predictors of developing symptomatic gallstone disease following bariatric surgery.

To study the incidence and predictors of developing symptomatic gallstone disease following bariatric surgery.

A retrospective study with prospective collective data will be conducted including all patients underwent bariatric surgery in general surgical department, Sohag University between January 2015 and December 2022 who did not have gallstones in the preoperative abdominal ultrasound examinations.

Medical records will be reviewed. Demographic data such as age, gender, BMI, comorbidities as ( DM, hypertension and hyperlipidemia ) and time elapsed between the surgery to post-surgery US examination. The findings of the US examinations will be collected and analyzed. Data will be analyzed to obtain descriptive and inferential statistics.

Eligibility Criteria:
Inclusion Criteria:

* All adult patients underwent bariatric surgery with minimum postoperative follow up period of one year duration will be included in the study.

Exclusion Criteria:

* Patients who had cholecystectomy during the bariatric surgery.
* Pediatric age.
Genetic Analysis of Familial Cases of Premature Ovarian Failure

The Premature ovarian failure (POF) is a rare syndrome observed in women under 40 who induced estrogen deficiency and often leads to infertility final. The etiologies of POF remain unknown in more than 85% of cases. There are 5-10 % of familial cases.The main objective of this study is to recruit, phenotype and genotype 20 families with at least two subjects with nonsyndromic POF in order to identify new loci using a single technical standard nucleotide polymorphisms (SNPs). This study will also include related population and population control.

It was decided to move towards a study of familial cases of IOP. This study will identify areas of susceptibility in new families, identify candidate genes, sequence these genes in cases familial POF and sporadic cases in order to detect potential mutations, and in the control population.

Eligibility Criteria:
Inclusion Criteria:

Patients of familial cases of POF :

* Female subjects between 16 and 40 years or women older than 40 years with a cessation of ovarian function before the age of 40 years with increased levels of FSH
* Primary or secondary amenorrhea for more than three months with LH and FSH\> 30mUI/ml
* No cases of fragile X syndrome in the family or blepharophimosis syndrome
* At least two cases in the family
* Origin Caucasian
* Patient signing the consent form for at least the blood sample
* Patient with Social Security

Population Index related topics :

* The presence of cycles until the age of 40 years with proven fertility, at least one child
* Amenorrhea and FSH\> 30mUI/ml according to the criteria of the index subject
* Men of the family of index case

Population control :

* Women of Caucasian origin
* Women who had regular cycles until at least age 40 and at least one child
* Lack of land autoimmune (no history of thyroid disease or diabetes type 1)
* Woman signing the consent form for at least the blood sample

Exclusion Criteria:

* Blood donation of more than 450ml in the previous three months.
* Subject with an abnormal karyotype in favor of Turner syndrome or having a premutation of the FMR1 gene or a syndromic form
* Subject exclusion period in another study without direct individual benefit
* Subject refusing to sign the consent form
Frequency Specific Microcurrent for the Treatment of Diastasis Recti

Determine if frequency specific microcurrent therapy improves pain management of DRA by 30% or greater.

Females aged 18 years or older who are postpartum from a singleton gestation status post vaginal and with diastasis recti will be recruited. The aim of this study is to determine if frequency specific microcurrent therapy improves pain management of DRA by 30% or greater

Improving DRA after microcurrent therapy in post-partum females may allow a faster, more effective return to activity thereby improving the return-to-duty transition and establishing personal readiness by meeting military fitness standards.

Eligibility Criteria:
\*\*Patients must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study\*\*

Inclusion Criteria:

* Active Duty and DoD beneficiary Postpartum Females (12 hours to 24 hours) with Diastasis Rectus Abdominus (DRA) pain
* Aged 18 years or older
* Singleton gestation/delivered (one baby carried and born)
* Vaginal delivery
* Nulliparous (first pregnancy) or multiparous (more than one pregnancy in the past)

Exclusion Criteria:

* less than 18 years of age
* females greater than 24 hours post-partum
* Medical history to include pacemaker
* History of arrhythmia
* Transplant status
* Insulin pump
* Pain pump
* Active cancer
* Inability to measure IRD
* Delivery via caesarean section
* Operative vaginal delivery (vacuum or forceps)
* 3rd or 4th degree vaginal laceration
CUHK Jockey Club HOPE 4 Care Programme - FES Bike

The Hong Kong Jockey Club Charities Trust has supported CUHK to launch a three-year project 'CUHK Jockey Club HOPE4Care Programme' to implement four evidence-based advanced rehabilitation technologies in 40 local elderly day care centres and rehabilitation centres, to benefit the community.

Our research team had developed the "Interactive FES Cycling System" that can be used as tools for rehabilitation by individuals who have suffered from a stroke or elderly. The system can integrate both motor power and muscle power in order to facilitate an active rehabilitative exercise.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of ischemic brain injury or intracerebral haemorrhage shown by magnetic resonance imaging or computed tomography after the onset of stroke;
* Significant gait deficit (Functional Ambulatory Category, FAC\<4 \[person cannot walk independently\]).

Exclusion Criteria:

* Any additional medical or psychological condition that would affect their ability to comply with the study protocol, e.g., a significant orthopaedic or chronic pain condition, major post-stroke depression, epilepsy, artificial cardiac pacemaker / joint;
* Severe hip, knee or ankle contracture that would preclude passive range of motion of the leg (MAS\<3).
Study of STP938 in Advanced Solid Tumours

The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy.

The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.


Eligibility Criteria:
Main Inclusion Criteria:

* Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.
* Male or female aged ≥ 18 years.
* Advanced disease not curable by available therapies and requires systemic therapy.
* Histologically confirmed diagnosis of eligible cancer type.
* Must have tumor tissue available for biomarker testing.
* Measurable disease (Part 1) and measurable disease per RECIST (Part2)
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
* Life expectancy \> 3 months as assessed by the Investigator.
* Adequate organ function (bone marrow, hepatic, renal function and coagulation).
* All toxicities (except alopecia) from prior cancer treatments or procedures must have resolved to ≤Grade 1 or returned to baseline levels prior to enrollment.

Main Exclusion Criteria:

* Pregnant or breastfeeding females and women of childbearing potential or males unwilling to comply with contraception requirements.
* Known active or symptomatic CNS metastases, carcinomatous meningitis, leptomeningeal disease or a history of spinal cord compression
* Active malignancy within 2 years of study enrollment
* Prior radiation within 2 weeks of start of therapy.
* Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or \<5 half-lives since completion of previous investigational therapy, whichever is shorter.
* Uncontrolled intercurrent illness.
* Immunocompromised subjects with increased risk of opportunistic infections or history of opportunistic infection in the last 12 months.
* Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection.
* Subjects with corrected QT interval \>470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems

Study to look at safety and effectiveness of different doses of tadalafil on prostate related genital/urinary tract problems.


Eligibility Criteria:
Inclusion Criteria:

* 6 month history of lower urinary tract symptoms either obstructive and/or irritative secondary to prostate related problems as diagnosed by a urologist.
* Stopped using treatments at least four weeks prior to study and agree to not use any other treatments during the study.
* Meet required prostate symptom score and urine flow rate.

Exclusion Criteria:

* Serum prostate specific antigen (PSA) greater than 10 (between 4 and 10, inclusive, without a negative biopsy w/in the last 6 months.
* Prostate removal and various other pelvic surgeries.
* Neurological disease or condition known to affect the bladder.
* Clinical evidence of prostate cancer, urinary tract inflammation or infection, including prostatitis.
* Have taken medications such as nitrates, finasteride, or dutasteride within the year.
C2 Esophageal Squamous Epithelium Dysplasia

This study will evaluate the efficacy and safety of C2 CryoBalloonTM Ablation System for the cryoablation of dysplastic squamous tissue in patients with moderate to severe esophageal squamous epithelium dysplasia.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female of 18 to 80 years old (including 18 and 80 years old).
2. At least one unstained lesion (USL) in the esophagus upon high resolution upper gastrointestinal endoscopy with Lugol's staining. Flat (Paris type 0-IIb) USL, with the total area of one or more USLs having a maximum longitudinal size of 6 cm and covering a maximum of one-half of the esophageal circumference.
3. Patients with one or more biopsy confirmed esophageal squamous epithelium dysplasia areas within 6 months prior to enrollment, and the pathological diagnosis is moderate to severe esophageal squamous epithelium dysplasia.
4. No potential of lymph node metastasis by preoperative comprehensive evaluation.

Exclusion Criteria:

Inclusion criteria:

1. Male or female of 18 to 80 years old (including 18 and 80 years old).
2. At least one unstained lesion (USL) in the esophagus upon high resolution upper gastrointestinal endoscopy with Lugol's staining. Flat (Paris type 0-IIb) USL, with the total area of one or more USLs having a maximum longitudinal size of 6 cm and covering a maximum of one-half of the esophageal circumference.
3. Patients with one or more biopsy confirmed esophageal squamous epithelium dysplasia areas within 6 months prior to enrollment, and the pathological diagnosis is moderate to severe esophageal squamous epithelium dysplasia.
4. No potential of lymph node metastasis by preoperative comprehensive evaluation.
5. The patients are self volunteered to participate in the trial and will sign an informed consent form prior to enroll.

Exclusion criteria:

1. Females who are pregnant, lactating or plan to get pregnant during the study.
2. Known hypersensitivity to iodine.
3. Lesions within the target area such as: obvious ulcer; varices at risk of bleeding; active inflammation due to esophageal reflux into the treatment area; lesions view being not flat, or containing unfavourable unstained lesions (USLs) outside the designated treatment areas.
4. Esophageal stenosis preventing the passage of the endoscope to the treatment area. Esophageal stenosis or stricture preventing advancement of a therapeutic endoscope within 4 cm of the treatment area.
5. Having previously received Heller surgery: any previous ablative esophageal surgery (photodynamic therapy, multipolar electrical coagulation, argon plasma coagulation, laser treatment) or any previous esophageal surgery except for anti-reflux surgery.
6. Suffering from any cancer in the past 5 years.
7. Severe bleeding potential; patients on anti-coagulative therapy or stopping using anti-coagulative drugs for less than 7 days before enrollment or with impaired coagulation.

9) Patients with unstable vital signs 10) Anti-human immunodeficiency virus (HIV) antibody positive, both syphilis serology Treponema pallidum-specific antibody test and rapid plasma reagin positive.

-
Promotion of Emotional Well-being in Hospitalized Cancer Patients by Information and Communication Technologies (ICTs)

The aim of this study is to test the efficacy of a brief psychological intervention composed by two therapeutic modules (virtual environments and reminiscence techniques) for the promotion of wellbeing of hospitalized adult cancer patients. Participants are randomly assigned to 2 conditions: intervention condition and control condition.


Eligibility Criteria:
Inclusion Criteria:

* adults with any cancer diagnosis
* hospitalized for at least 1 week
* Karnofsky functional state ≥50
* life expectancy ≥2 months

Exclusion Criteria:

* serious psychopathology
* cognitive impairment
Evaluating the Patient-Ventilator Synchrony During Mechanical Ventilation in Patients With Acute Lung Injury

The overall purpose to the study is to prospectively study how often patients with and without acute lung injury (ALI) have patient-ventilator asynchrony demonstrated as stacked breaths. The investigators seek to describe the quantity of stacked breaths by continuously recording flow, volume, and pressure waveforms routinely displayed on the vent. The investigators also seek to describe how primary ICU teams manage asynchrony documenting interventions of sedation or vent manipulation and what modality is most successful.


Eligibility Criteria:
Inclusion Criteria:

age \> 18 years intubated and mechanically ventilated diagnosed with acute lung injury (ALI) or requiring mechanical ventilation for reasons other than ALI

Exclusion Criteria:

neurological deficits (acute or chronic) that prevent effective diaphragm activity.

* Neuromuscular disease affecting the diaphragm
* Neuromuscular blockade
The Turkish Version of the Musculoskeletal Pain Intensity and Interference Questionnaire for Musicians (MPIIQM-T)

The aim of this study, original named "The musculoskeletal pain intensity and interference questionnaire (MPIIQM)" is the Turkish validation, reliability and cross-cultural validation of the questionnaire.


Eligibility Criteria:
Inclusion Criteria:

* permanent musician in an orchestra
* understand and reading Turkish

Exclusion Criteria:

* freelance musician
Digital Transformation of Continuity of Care for Peripherally Inserted Central Catheters: SpadCare Experience

The study focuses on patients who require outpatient infusion of therapy ("Infusions, Intravenous"\[Mesh\]) "Administration, Intravenous"\[Mesh\] ("Home Infusion Therapy"\[Mesh\]) "Parenteral Nutrition, Home"\[Mesh\] via a peripherally inserted central catheter (PICC) ("Central Venous Catheters"\[MeSH\] "Catheterization, Central Venous"\[MeSH\] "Catheterization, Peripheral" \[MeSH\] "Vascular Access Devices"\[Mesh\] )

The patients, who receive training ("Patient Education as Topic"\[Mesh\] "patient participation"\[MeSH Terms\] ) via an app on their personal mobile phone ("User-Computer Interface"\[Mesh\] "Smartphone"\[MeSH\] "Mobile Applications"\[MeSH\] "Computers, Handheld"\[Mesh\] "Digital Health"\[Mesh\] are able to perform specialized care ("Nursing"\[Mesh\]) Care"\[MeSH\] "Delivery of Health Care"\[Mesh:NoExp\] "Home Nursing"\[MeSH\] "Self Administration"\[Mesh\] to reduce complications ("adverse effects"\[MeSH Subheading\] "Catheter-Related Infections"\[Mesh\] ) so that they are monitored in real time by those responsible for the catheter. ("Telemedicine"\[Mesh\]

Eligibility Criteria:
Inclusion Criteria:

* Patients \>18 years.
* Sign the informed consent form.
* Have a Smartphone and accept the use of the APP.
* Patient with a PICC inserted by the Infusion and Vascular Access Team of the University Hospital of Navarra and with a planned use of at least one month.

Exclusion Criteria:

* Patients with limitations in the use of digital resources or lack of Smartphone.
* Patients who do not want to install the APP on their Smartphone
* Patients who do not authorize access to their Computerized Medical Record (HCI).
Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use

The goal of this project is to conduct a pilot study evaluating feasibility, acceptability, and estimating the effect size of a new computerized Motivational Enhancement Therapy (cMET) intervention for alcohol-involved adolescent primary care patients.

The goal of this project is to conduct a pilot study evaluating feasibility, acceptability, and estimating the effect size of a new computerized Motivational Enhancement Therapy (cMET) intervention for alcohol-involved adolescent primary care patients. The investigators hypothesize that 1) cMET, when added to Computerized Alcohol Screening and Brief Intervention (cASBI), (cASBI+cMET) will be feasible and acceptable when used in primary care; and 2) 12- to 18-yr old patients receiving cASBI+cMET will have lower rates of any alcohol use, days of alcohol use, drinks per drinking day, and days of heavy episodic drinking, than cASBI alone.

Eligibility Criteria:
Inclusion Criteria:

* any alcohol use days in the past 90 days
* have an email address and internet access at home, school, or library

Exclusion Criteria:

* unable to read or understand English
* living away at college at the time of the recruitment visit
* not available for computer/telephone follow-ups
* judged by the provider to be medically or emotionally unstable at time of visit